Kore Private Wealth’s Ultragenyx Pharmaceutical RARE Stock Holding History

Kore Private Wealth’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-250	Closed	-$19K	–	882
2020 Q2	$19K	Hold	250	–	–	﹤0.01%	657
2020 Q1	$11K	Hold	250	–	–	﹤0.01%	680
2019 Q4	$11K	Buy	+250	New	+$10.3K	﹤0.01%	728
2019 Q2	–	Sell	-250	Closed	-$17K	–	652
2019 Q1	$17K	Hold	250	–	–	﹤0.01%	532
2018 Q4	$11K	Buy	+250	New	+$13.7K	﹤0.01%	561

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Kore Private Wealth's RARE Position: Q3 2020 in Review

Kore Private Wealth sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2020, closing a stake of 250 shares — an estimated $19K sold.

Kore Private Wealth first reported a position in RARE in Q4 2018 and held it in 5 quarters. The position peaked at $19K in Q2 2020. 207 funds tracked by Wall St. Rank hold RARE as of Q3 2020.

Kore Private Wealth reported no remaining Ultragenyx Pharmaceutical position as of Q3 2020 after selling out during the quarter.
Kore Private Wealth sold 250 Ultragenyx Pharmaceutical shares in Q3 2020, an estimated $19K.
Kore Private Wealth first reported a position in Ultragenyx Pharmaceutical in Q4 2018 and held it in 5 quarters.
Kore Private Wealth's Ultragenyx Pharmaceutical position peaked at $19K in Q2 2020.
207 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.